Fortress Biotech, Inc. develops and commercializes pharmaceutical and biotechnology products. The company develops CNDO-109, a lysate that treats cancer-related and other conditions; tramadol HCl for managing postoperative pain; CAEL-101 for the treatment of amyloid light chain amyloidosis; and CEVA101 for severe traumatic brain injury in children and adults in the United States. It also develops CK-301 for treating patients with non-small cell lung cancer (NSCLC); CK-101 for the treatment of patients with epidermal growth factor receptor mutation-positive NSCLC; and antibodies that target glucocorticoid-induced TNFR-related protein and carbonic anhydrase IX, as well as anti-cancer agents that inhibit bromodomain and extra-terminal proteins, and poly polymerase. In addition, the company develops CUTX-101 for treating Menkes disease; preclinical adeno-associated virus gene therapies for treating mucopolysaccharidosis type 1, dysferlinopathies, and corneal transplant rejection; Triplex, which is in Phase II clinical study for preventing and treating cytomegalovirus (CMV); and Pentamer, a vaccine drug candidate for preventing CMV. Further, it offers Targadox, a tablet for severe acne; Luxamend wound cream; Ceracade for treating dry skin conditions; Triderm for treating eczema, dermatitis, allergies, and rash; and chimeric antigen receptor and engineered T cell therapies across various cancers. Additionally, it provides retail brokerage and wealth management services to high net worth individual and institutional clients; investment banking, merger and acquisition, and advisory services to micro, small, and mid-cap high growth companies; trades in securities; liquidity services; and tax preparation, fixed insurance sales, and licensed mortgage brokerage services. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was founded in 2006 and is based in New York, New York..
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone781-652-4500
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$26.88 million
Profitability
Miscellaneous
Employees68
Next Earnings Date8/8/2019 (Estimated)
OptionableOptionable
Fortress Biotech (NASDAQ:FBIO) Frequently Asked Questions
What is Fortress Biotech's stock symbol?
Fortress Biotech trades on the NASDAQ under the ticker symbol "FBIO."
How were Fortress Biotech's earnings last quarter?
Fortress Biotech (NASDAQ:FBIO) posted its earnings results on Monday, March, 18th. The biopharmaceutical company reported ($0.58) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.58). Fortress Biotech had a negative net margin of 30.52% and a negative return on equity of 136.24%. View Fortress Biotech's Earnings History.
When is Fortress Biotech's next earnings date?
What price target have analysts set for FBIO?
1 equities research analysts have issued 12 month target prices for Fortress Biotech's shares. Their forecasts range from $11.00 to $11.00. On average, they expect Fortress Biotech's stock price to reach $11.00 in the next year. This suggests a possible upside of 494.6% from the stock's current price. View Analyst Price Targets for Fortress Biotech.
What is the consensus analysts' recommendation for Fortress Biotech?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fortress Biotech in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Fortress Biotech.
What are Wall Street analysts saying about Fortress Biotech stock?
Here are some recent quotes from research analysts about Fortress Biotech stock:
- 1. According to Zacks Investment Research, "Fortress Biotech, Inc. is a biopharmaceutical company. The company is engaged in acquiring, developing and commercializing novel pharmaceutical and biotechnology products. Fortress Biotech, Inc., formerly known as Coronado Biosciences, Inc., is based in NEW YORK, United States. " (5/16/2019)
- 2. HC Wainwright analysts commented, "Valuation and risks to price target achievement. We reiterate our Buy rating and $11 price target. Our valuation is based on our clinical net present value (NPV) model, which derives value from across Fortress’ subsidiaries. This model allows us to flex multiple assumptions affecting a drug’s potential commercial profile. Factors which could impede reaching our price target include failed or inconclusive clinical trials or inability of the company to secure adequate funding to progress its drugs through the development pathway." (5/13/2019)
Has Fortress Biotech been receiving favorable news coverage?
Media stories about FBIO stock have been trending somewhat negative this week, according to InfoTrie. The research group scores the sentiment of news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Fortress Biotech earned a media sentiment score of -1.8 on InfoTrie's scale. They also gave news stories about the biopharmaceutical company a news buzz of 9.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the next few days.
Who are some of Fortress Biotech's key competitors?
Some companies that are related to Fortress Biotech include Corbus Pharmaceuticals (CRBP), Vital Therapies (VTL), Milestone Pharmaceuticals (MIST), Corium International (CORI), BioSpecifics Technologies (BSTC), DiaMedica Therapeutics (DMCAF), INDIVIOR PLC/S (INVVY), ProQR Therapeutics (PRQR), Evolus (EOLS), NextCure (NXTC), Cyclerion Therapeutics (CYCN), Kalvista Pharmaceuticals (KALV), Albireo Pharma (ALBO), Savara (SVRA) and Arcus Biosciences (RCUS).
What other stocks do shareholders of Fortress Biotech own?
Who are Fortress Biotech's key executives?
Fortress Biotech's management team includes the folowing people:
- Dr. Lindsay Allan Rosenwald, Exec. Chairman, Pres & CEO (Age 64)
- Dr. Eric K. Rowinsky, Co-Vice Chairman & Consultant (Age 62)
- Mr. Michael S. Weiss, Exec. Vice Chairman of Strategic Devel. (Age 53)
- Ms. Robyn M. Hunter, CFO, Treasurer & Corp. Sec. (Age 57)
- Mr. George C. Avgerinos, Sr. VP of Biologics Operations (Age 65)
Who are Fortress Biotech's major shareholders?
Fortress Biotech's stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (2.88%), Northern Trust Corp (0.70%), Strs Ohio (0.49%), Cpwm LLC (0.30%), Acadian Asset Management LLC (0.24%) and Jacobs Levy Equity Management Inc. (0.20%). Company insiders that own Fortress Biotech stock include George Avgerinos, Lindsay A Md Rosenwald and Robyn Hunter. View Institutional Ownership Trends for Fortress Biotech.
Which institutional investors are selling Fortress Biotech stock?
FBIO stock was sold by a variety of institutional investors in the last quarter, including Jacobs Levy Equity Management Inc., Strs Ohio, Morgan Stanley, BlackRock Inc. and Acadian Asset Management LLC. Company insiders that have sold Fortress Biotech company stock in the last year include George Avgerinos and Robyn Hunter. View Insider Buying and Selling for Fortress Biotech.
Which institutional investors are buying Fortress Biotech stock?
FBIO stock was acquired by a variety of institutional investors in the last quarter, including Northern Trust Corp, Cpwm LLC, Dowling & Yahnke LLC, Charles Schwab Investment Management Inc., State of Wisconsin Investment Board and National Asset Management Inc.. View Insider Buying and Selling for Fortress Biotech.
How do I buy shares of Fortress Biotech?
Shares of FBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Fortress Biotech's stock price today?
One share of FBIO stock can currently be purchased for approximately $1.85.
How big of a company is Fortress Biotech?
Fortress Biotech has a market capitalization of $120.68 million and generates $26.88 million in revenue each year. The biopharmaceutical company earns $-84,150,000.00 in net income (profit) each year or ($3.01) on an earnings per share basis. Fortress Biotech employs 68 workers across the globe.
What is Fortress Biotech's official website?
How can I contact Fortress Biotech?
Fortress Biotech's mailing address is 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014. The biopharmaceutical company can be reached via phone at 781-652-4500 or via email at [email protected]
MarketBeat Community Rating for Fortress Biotech (NASDAQ FBIO)
MarketBeat's community ratings are surveys of what our community members think about Fortress Biotech and other stocks. Vote "Outperform" if you believe FBIO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FBIO will underperform the S&P 500 over the long term. You may vote once every thirty days.
